NCT04330625 2022-11-08Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)Duke UniversityPhase 1 Terminated1 enrolled
NCT01470209 2018-03-19A Phase I Study of BKM120 and Everolimus in Advanced Solid MalignanciesEmory UniversityPhase 1 Completed43 enrolled